⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.
JBCHEPHARM - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 4.1
| Stock Code | JBCHEPHARM | Market Cap | 34,104 Cr. | Current Price | 2,123 ₹ | High / Low | 2,177 ₹ |
| Stock P/E | 46.9 | Book Value | 238 ₹ | Dividend Yield | 0.73 % | ROCE | 25.9 % |
| ROE | 20.2 % | Face Value | 1.00 ₹ | DMA 50 | 1,982 ₹ | DMA 200 | 1,827 ₹ |
| Chg in FII Hold | -0.76 % | Chg in DII Hold | -0.12 % | PAT Qtr | 179 Cr. | PAT Prev Qtr | 200 Cr. |
| RSI | 64.8 | MACD | 47.2 | Volume | 4,35,699 | Avg Vol 1Wk | 5,47,625 |
| Low price | 1,303 ₹ | High price | 2,177 ₹ | PEG Ratio | 1.97 | Debt to equity | 0.01 |
| 52w Index | 93.9 % | Qtr Profit Var | 14.6 % | EPS | 46.5 ₹ | Industry PE | 27.6 |
📊 Core Financials
- Revenue Growth: PAT declined slightly (₹179 Cr vs ₹200 Cr)
- Profit Margins: Strong with ROE at 20.2% and ROCE at 25.9%
- Debt Ratios: Very low (Debt-to-Equity 0.01), excellent financial stability
- Cash Flows: Dividend yield of 0.73% provides modest shareholder returns
- Return Metrics: Efficient capital utilization compared to peers
💹 Valuation Indicators
- P/E Ratio: 46.9 (well above industry average of 27.6, overvalued)
- P/B Ratio: ~8.9 (Price ₹2,123 / Book Value ₹238)
- PEG Ratio: 1.97 (suggests growth premium priced in)
- Intrinsic Value: Appears stretched given valuation multiples
🏢 Business Model & Competitive Advantage
- Pharmaceutical company with diversified product portfolio
- Strong presence in generics and formulations
- Competitive advantage lies in scale, distribution, and consistent profitability
📈 Entry Zone Recommendation
- Current Price: ₹2,123
- Support Zone: ₹1,950 – ₹2,000 (near DMA 50 & DMA 200)
- Long-term Holding: Attractive for investors seeking pharma exposure, but caution due to high valuation
✅ Positive
- High ROCE and ROE indicate strong efficiency
- Low debt ensures financial resilience
- Dividend yield adds shareholder value
⚠️ Limitation
- P/E ratio significantly above industry average
- P/B ratio relatively high compared to peers
- Quarterly PAT declined (₹179 Cr vs ₹200 Cr)
📉 Company Negative News
- FII holdings decreased (-0.76%), showing reduced foreign investor confidence
- Quarterly PAT decline reflects earnings pressure
📈 Company Positive News
- DII holdings increased (+0.12%), showing domestic support
- Quarterly profit variation of 14.6% YoY indicates growth stability
- MACD positive (47.2) suggests improving technical trend
🌐 Industry
- Pharmaceutical industry remains resilient with global demand
- Industry P/E at 27.6 highlights JBCHEPHARM trading at a premium
🔎 Conclusion
JBCHEPHARM demonstrates strong fundamentals with high efficiency, low debt, and consistent profitability. However, stretched valuations and modest earnings growth limit upside. Entry around ₹1,950–₹2,000 may provide a safer margin. Long-term holding is suitable for investors seeking exposure to pharma, but monitoring valuation and earnings trajectory is essential.